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Cyclic AMP is a ubiquitous intracellular second messenger involved in the regulation
of a wide variety of cellular processes, a majority of which act through the cAMP –
protein kinase A (PKA) signaling pathway and involve PKA phosphorylation of specific
substrates. PKA phosphorylation events are typically spatially restricted and temporally
well controlled. A-kinase anchoring proteins (AKAPs) directly bind PKA and recruit it
to specific subcellular loci targeting the kinase activity toward particular substrates,
and thereby provide discrete spatiotemporal control of downstream phosphorylation
events. AKAPs also scaffold other signaling molecules into multi-protein complexes
that function as crossroads between different signaling pathways. Targeting AKAP
coordinated protein complexes with high-affinity peptidomimetics or small molecules to
tease apart distinct protein–protein interactions (PPIs) therefore offers important means
to disrupt binding of specific components of the complex to better understand the
molecular mechanisms involved in the function of individual signalosomes and their
pathophysiological role. Furthermore, development of novel classes of small molecules
involved in displacement of AKAP-bound signal molecules is now emerging. Here, we
will focus on mechanisms for targeting PPI, disruptors that modulate downstream cAMP
signaling and their role, especially in the heart.
Keywords: cAMP, AKAP, protein–protein interaction, heart, disruptor peptide, small molecule
Introduction
Intracellular 3′-5′-cyclic adenosine monophosphate (cAMP) is an important second messenger
that regulates a number of biological processes. Even though cAMP is diﬀusible, its concentration
and signaling are tightly controlled and coordinated through the involvement of a molecular
machinery coordinating the spatial and temporal processes of localized cAMP signaling events.
Signal transduction through the cAMP pathway starts by stimulation of G-protein-coupled-
receptors (GPCRs), via speciﬁc extracellular ligands leading to activation of adenylyl cyclase
(AC), which converts ATP into cAMP. The rise in intracellular cAMP levels leads to a set
of events mediated by speciﬁc eﬀector molecules, hereunder protein kinase A (PKA; Walsh
et al., 1968), cyclic nucleotide gated ion channels (Brown et al., 1979) and exchange protein
directly activated by cAMP (Epac; de Rooij et al., 1998; Kawasaki et al., 1998). To terminate
the signal, intracellular cAMP levels must be brought back to basal levels; this is attained by
cyclic nucleotide phosphodiesterases (PDEs), which hydrolyse cAMP and/or cGMP. Additionally,
cAMP signalosomes targeted to speciﬁc subcellular locales by A-kinase anchoring proteins
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(AKAPs) bring together signal initiators, eﬀector and terminators
in supramolecular signaling complexes. The existence of these
speciﬁc complexes (illustrated in Figure 1) governed by protein–
protein interactions (PPIs) creates an opportunity for new
therapeutic strategies to control cAMP dependent signaling
that is out of tune or involved in pathologies. In this review
we will ﬁrst focus on signaling through AKAP-coordinated
complexes, next on targeting PPIs as a possible strategy to
control and regulate cAMP signaling events and ﬁnally mention
a few examples of possible PPIs that could be targeted. We will
discuss cAMP/PKA/AKAP signaling in general terms but will
particularly focus on the heart, where cAMP signaling pathways
are involved in diﬀerent stages of the cardiac cycle and in several
pathologies.
cAMP Compartmentation
Cyclic AMP is a ubiquitous intracellular second messenger
involved in the regulation of a wide variety of cellular processes.
For this reason there are molecular mechanisms that rigorously
control cAMP signal responses, intimately linked with spatial
and temporal ﬁne tuning. The ﬁrst indication that cAMP
could be organized in speciﬁc microdomains came in the
early 1980s, when diﬀerent GPCR ligands were observed to
trigger very diﬀerent cardiomyocytes responses, even if there
was a similar increase in cAMP levels (Hayes et al., 1980).
Meanwhile, the development of new methodologies to study
compartmentation (for example, ﬂuorescent resonance energy
FIGURE 1 | Schematic illustration of cAMP signaling pathways.
Stimulation of G-protein-coupled receptors leads to activation of adenylyl
cyclase (AC), which converts ATP into cAMP. cAMP increases in local
microdomains and binds to different effectors such as protein kinase A (PKA),
cyclic nucleotide gated ion channels and exchange protein directly activated
by cAMP (Epac) leading to specific downstream effects. Cyclic nucleotide
phosphodiesterases (PDEs) hydrolyse cAMP into AMP and terminates the
signal. A-kinase anchoring proteins (AKAPs) anchor the signaling molecules
involved in the pathway and target them to specific organelles in the cell.
transfer FRET, reviewed in Zaccolo and Pozzan, 2002; Smith
et al., 2006) provided solid evidence of cAMP dynamics and of
the mechanisms and proteins involved.
First, an important starting point for generation of well-
deﬁned local gradients of cAMP is the organization and diverse
expression of receptors, G proteins and associated cyclases at the
plasma membrane. The G proteins are heterotrimeric, guanosine
triphosphate-binding (GTP-binding) proteins, assembled from
three subunits: α-, β- and γ-. There are more than 20 diﬀerent
Gα-subunits that can activate or inhibit diﬀerent eﬀectors. For
example, Gαs activates and Gαi inhibits ACs, respectively. Like
G proteins, AC exist in diﬀerent isoforms in mammals, most of
them are associated with the plasma membrane (AC1-9) whereas
AC10 is soluble (Steegborn, 2014). Both G proteins and AC
isoforms have also been reported in lipid rafts and caveolae,
and implicated in the generation of local cAMP microdomains
at the membrane (Ostrom and Insel, 2004; Patel et al., 2008).
Additionally, it was recently shown that cAMP production
does not exclusively occur at the plasma membrane and is not
terminated when receptors are internalized (Calebiro et al., 2009;
Ferrandon et al., 2009). Moreover, Irannejad et al. (2013) have
shown GPCR signaling both in the plasma membrane and after
internalization in living cells using a biosensor. In summary,
both G proteins and ACs have a distribution that contributes to
generation of local gradients of cAMP.
Second, the expression and availability of various eﬀector
molecules in cAMP microdomains also contribute to discretely
controlling how the signal is propagated (Mei et al., 2002;
Bresnnesvik et al., 2005; Bacallao and Monje, 2013; Vitali
et al., 2014). The speciﬁcity introduced by diﬀerent cAMP
eﬀector molecules is illustrated, for example in the heart
where it was shown that Epac modulates cardiac sarcomeric
contraction despite a decrease in Ca2+ levels, while PKA
modulates contractility via an increase in intracellular Ca2+
(Cazorla et al., 2009). Here, we will not go into details with
respect to cAMP-gated ion channels and Epac, however, cAMP
eﬀectors can perform both synergistically and antagonistically
in the regulation of speciﬁc cellular functions and coordinated
action may have biological signiﬁcance (reviewed in Craven
and Zagotta, 2006; Cheng et al., 2008). The PKA holoenzyme
is a tetramer composed of regulatory (R) subunit dimer and
two catalytic (C) subunits, which are associated in the inactive
state when cAMP intracellular levels are low. When cAMP
levels increase PKA becomes activated; this proceeds by a
concerted reaction where cAMP molecules bind cooperatively
to the two cyclic nucleotide binding domains (CNBD) in
each R-subunit of PKA leading to a conformational change
by releasing the C-subunit. The free C-subunit becomes active
and can then phosphorylate speciﬁc serine/threonine residues
in target proteins, usually in the sequence Arg-Arg-X-Ser/Thr,
where X is a hydrophobic amino acid. There are two types of
PKA holoenzymes, type I and type II, that mainly diﬀer in their
localization and aﬃnity for cAMP and with diﬀerent R-subunit
composition (RI and RII) (Reimann et al., 1971; Corbin et al.,
1975; Cadd et al., 1990; Dostmann and Taylor, 1991; Gamm
et al., 1996). Both R-subunits are very similar concerning their
domain organization which includes the N-terminal docking
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and dimerization (D/D) domain important for localization
inside the cell, a substrate/auto-inhibitor region that binds to
the C-subunit in the holoenzyme and in the C-terminal two
highly conserved CNBDs (Corbin et al., 1978; Doskeland, 1978).
Although, both RI and RII share the same organization their
substrate/auto-inhibitor region is signiﬁcantly diﬀerent, in that
RII can be autophosphorylated whereas RI contains a pseudo-
phosphorylation site. Another diﬀerence between PKA-RI and
PKA-RII is their localization, where PKA type I is primarily found
in the cytosol while PKA type II is predominantly localized to
speciﬁc cellular organelles (Tasken and Aandahl, 2004;Wong and
Scott, 2004). Additionally, PKA type I and type II also diﬀer from
each other in their cAMP activation constants which is lower
for type I than for type II (typically 50–100 nM versus 200–
400 nM; Dostmann and Taylor, 1991). PKA exist in diﬀerent
isoform combinations encoded by diﬀerent genes, four C-subunit
isoforms (in human Cα, Cβ, Cγ, and PRKX) and four R-subunit
isoforms (RIα, RIβ, RIIα, and RIIβ). In combination these
diﬀerent R- and C-subunits isoforms can form diﬀerent PKA
holoenzymes that can be present in diverse signalosomes with
distinct expression patterns in diﬀerent tissues and cell types.
Third, intracellular gradients of cAMP and consequently their
signaling pathways are highly controlled by PDEs. They are key
players in controlling intracellular cAMP levels due to the fact
that PDEs are the only cAMP degrading enzymes. PDEs catalyze
the degradation of cAMP by breaking the phosphodiesterase
bound resulting in adenosine-5-monophosphate (AMP). PDEs
are highly conserved between species, with around 50 diﬀerent
isoforms that are part of 11 families (PDE1-11) with diﬀerent
enzymatic and regulatory characteristics (Houslay and Milligan,
1997; Conti and Jin, 1999). They all share similarities in their
structure, mainly in the C-terminal catalytic domain, while the
N-terminal regulatory and targeting domains diﬀer (Bender and
Beavo, 2006; Conti and Beavo, 2007). PDEs can be cAMP-speciﬁc,
cGMP-speciﬁc or hydrolyse both. The great variety in isoforms,
their speciﬁc tissue and subcellular localization and the fact
that PDEs have diﬀerent enzymatic proﬁles, makes PDEs key
players in spatial and temporal control of intracellular cAMP
levels. In the heart, the cAMP-speciﬁc PDE4 and cAMP/cGMP
PDE3 are responsible for the majority of cAMP hydrolysed
in cardiomyocytes (Mongillo et al., 2004; Rochais et al., 2004;
Fischmeister et al., 2006; Mika et al., 2012).
Fourth, scaﬀold proteins coordinate the physical assembly
of components of a signaling pathway. In cAMP signaling
pathways AKAPs are responsible for the assembly of speciﬁc
signalosomes. They form complexes between PKAs and their
speciﬁc targets in localized subcellular domains, consequently
they are important contributors to compartmentation, which will
be further discussed in the next chapter.
AKAPs – Scaffold Proteins Involved
Assembly of Supramolecular Signaling
Complexes
The spatial and temporal organization of cAMP/PKA signaling is
attained by a carefully tuned balance between local activation of
the signal eﬀector and signal termination machinery assembled
and targeted by AKAPs. There are more than 50 AKAPs
identiﬁed, and even though they belong to a structurally diverse
family they all share the ability to enable tightly regulated
phosphorylation of substrates that are anchored to or localized in
the vicinity of AKAPs together with PKA (Tasken and Aandahl,
2004; Wong and Scott, 2004). The four main features that
characterize the AKAP complexes formed (Figure 2) are:
(1) Anchoring of the dimer R-subunit D/D-domain through
interaction between the hydrophobic pocket of PKA and the
FIGURE 2 | Schematic illustration of an A kinase anchoring protein (AKAP). AKAPs are categorized by four different characteristics. First, an amphipathic
α-helical region of the AKAP interacts with D/D-domain of the PKA R-subunit dimer. Second, they target the supramolecular complex to specific subcellular
localizations. Third, AKAPs may also hold PKA substrates by direct binding or by targeting in their vicinity. Lastly, AKAPs can also function as signaling scaffolds for
other signaling enzymes. In the absence of cAMP, PKA is inactive and its substrates are not phosphorylated, when cAMP levels increase it binds to the R-subunits
and the active catalytic subunits are free to phosphorylate their targets.
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14–18 amino acid amphipathic helix region of AKAPs (Carr
et al., 1991). AKAPs can bind both RI- and RII-subunits of
PKA, the majority binds to RII-subunits;
(2) Targeting to speciﬁc subcellular locations. AKAPs typically
contain a targeting domain that localizes the entire
AKAP/PKA complex inside the cell. This can be a deﬁned
organelle, membrane or structure and the bindingmay occur
by protein–protein or protein–lipid interactions.
(3) Directly binding to or co-localizing with speciﬁc substrates
that will be phosphorylated by PKA.
(4) Assembly of multi-protein complexes with additional
signaling enzymes such as PDEs, phosphatases (PPs), and
other kinases;
AKAPs can be found in a number of tissues and are involved
in the composition of a wide variety of complexes implicated
in diﬀerent signaling cascades (reviewed in Pidoux and Taskén,
2010; Tröger et al., 2012; Esseltine and Scott, 2013; Scott et al.,
2013). Most of these AKAP complexes preferentially anchor the
PKA type II holoenzyme with higher aﬃnity. There are, however,
some exceptions where AKAPs anchor PKA-RI. For example,
the cardiomyocyte sphingosine kinase interacting protein (SKIP)
exclusively binds PKA type I and facilitates phosphorylation of
ChChd3 inside mitochondria (Means et al., 2011). Recently a
small membrane AKAP (smAKAP) was found to target RI to
the plasma membrane (Burgers et al., 2012). There are also
some cases where AKAPs can have dual speciﬁcity, for example
D-AKAP1 and D-AKAP2 (Huang et al., 1997a,b), ezrin (Ruppelt
et al., 2007) and Opa1 (Pidoux et al., 2011) can bind both
RI and RII at physiological concentrations. There is also a
number of cellular contexts where AKAPs contribute to the
spatial organization of other eﬀectors such as Epac (Dodge-Kafka
et al., 2005). AKAPs complexes have been shown to directly
interact with PPs and PDEs which provides tight control of signal
termination, since PPs that remove phosphorylation or PDEs that
degrade cAMP are found in the same complex (Coghlan et al.,
1995; Schillace and Scott, 1999; Dodge et al., 2001; Tasken et al.,
2001).
In the heart the existence of a supramolecular complex
with PKA/mAKAP/PDE4D3 creates a negative feedback loop
mechanism under stimulation, where PDE4D3 phosphorylation
increases cAMP hydrolysis and turns oﬀ PKA activity (Dodge-
Kafka et al., 2005). Several AKAPs occur in diﬀerent isoforms
and spliced variants that are targeted to diﬀerent subcellular
localizations. For example, AKAP18 has several isoforms (α, β,
γ, and δ) that are localized to distinct subcellular structures in
speciﬁc cell types. Both AKAP18α and AKAP18β are mainly
found in plasma membrane, while AKAP18α is associated with
L-type Ca2+ channels in the skeletal muscle and pancreatic cells
less is known about AKAP18β function (Fraser et al., 1998; Gray
et al., 1998). When overexpressed in polarized epithelial kidney
cells, however, AKAP18α and AKAP18β preferentially localize
to the basolateral and apical membrane, respectively (Trotter
et al., 1999). Overexpressed AKAP18γ cloned from pancreas and
lung is mainly localized in the cytosol but it was also found
in the nucleus of mouse oocytes (Trotter et al., 1999; Brown
et al., 2003). AKAP18δ was ﬁrst found in the kidneys anchored
to vesicles (Henn et al., 2004) and later AKAP18γ/δ was found
in cardiomyocytes anchored to the sarcoplasmic reticulum (SR;
Lygren et al., 2007). Furthermore, AKAPs can target complexes
to other localizations like mitochondria, the Golgi complex,
centrosomes, cytoskeleton and many other loci (Wong and Scott,
2004; Tröger et al., 2012).
Several AKAPs have been found to be expressed in
cardiac tissue involved in diﬀerent processes: calcium-induced
calcium release in depolarization and plateau phase, cardiac
repolarization and cardiac remodeling due to stress responses
(Scott et al., 2013; Soni et al., 2014). It has been shown
that diﬀerent pathologies are associated with AKAPs, due to
polymorphisms and mutations in members of this family of
proteins, in heart diseases (Chen et al., 2007) and cancer
development (Frank et al., 2008). In the heart, AKAPs have
been implicated in several cardiac diseases such as rhythm
disorder, long-QT syndrome, cardiac hypertrophy and heart
failure (reviewed in Soni et al., 2014).
This review will focus on the potential targeting of AKAPs as
a therapeutic strategy.
Targeting Protein–Protein Interactions
There are a number of approaches to target signal eﬀector
and signal termination enzymes in speciﬁc signalosomes. One
strategy is the development of inhibitors against speciﬁc
enzymes and receptors. However, as signaling enzymes may
be components of several diﬀerent signalosomes, speciﬁcity
may not be at the level of the individual type of complex.
Another possibility would be to target scaﬀold protein such
as AKAPs using RNA interference (RNAi). Small interfering
RNAs (siRNAs) can be speciﬁcally designed to target any gene
and can silence target mRNA expression to overcome diﬀerent
pathologies. Even though siRNA is been increasingly used and
some siRNA based therapies are in human clinical trials, siRNA
therapeutics still need to overcome the obstacles of eﬃcient drug
delivery to be a fully viable drug development strategy (for more
details about this approach see de Fougerolles et al., 2007). In
this review we will mainly focus on another approach, targeting
AKAPs by disrupting the binding between two proteins, i.e.,
interfering with PPIs.
Hundreds of thousands of PPIs probably occur in human
cells and are involved in assembly of supramolecular signaling
complexes and signalosomes as well as in target-depend signaling
by docking and adaptors. PPIs represent an exciting group
of potential therapeutic targets implicated in a wide array of
diseases. The fact that they are intrinsically associated with
speciﬁc signalosomes oﬀers potential for high speciﬁcity and
PPIs may therefore constitute valuable targets in new therapeutic
strategies. For this reason designing and developing PPI disruptor
peptides represents an area of increasing interest in target
validation and drug discovery. Peptides can be highly selective
and speciﬁc and their aﬃnity to the target makes them appealing
candidates in vivo due to minimal oﬀ-target eﬀects. Peptides
and peptidomimetics oﬀer several beneﬁts such as ease of
synthesis, optimization and evaluation, high aﬃnity, minimal
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immune responses and low toxicity. However, peptides can be
metabolically cleaved and rapidly cleared from body and non-
natural peptides or peptidomimetics that abandon the amino
acid backbone may be necessary to avoid excessive degradation.
Furthermore, intracellular delivery may be an issue (reviewed
in Cochran, 2000). Nevertheless, the development of disruptor
peptides for PPIs can be valuable research tools to perturb
supramolecular signaling complexes and retrieving information
regarding the role of the proteins involved.
During this time also disruptor peptides for complexes
involving AKAPs have been progressing, mainly to prevent
the interaction between AKAP and PKA. These peptides were
primarily designed to serve as tools to study AKAPs and
interaction with diﬀerent PKA R-subunits, both in vitro and
in situ inside cells. As mentioned above, AKAPs bind through
a conserved amphipathic helixes domain to the hydrophobic
dimerization domain of the PKA R-subunit (Carr et al., 1991).
These small disruptor peptides mainly mimic the amphipathic
helices domain of AKAP, like in the case of Ht31, the ﬁrst
and most commonly used disruptor peptide. This was derived
from the PKA binding domain in AKAP-Lbc (Carr et al., 1992)
and it was later shown to be non-selective, with the ability to
disrupt both RI and RII from AKAPs (Herberg et al., 2000).
More than 20 years later Ht31 is still being used as a tool to
describe new AKAPs, for example neurochondrin (Hermann
et al., 2015). In 2003, a disruptor peptide was developed by
determining the minimal binding domains of several AKAPs that
had high binding aﬃnity to RII, called AKAP-in silico (AKAP-IS;
Alto et al., 2003). A later version was developed to have almost
no RI-binding, SuperAKAP-IS (Gold et al., 2006). At the same
time, peptides designed to disrupt AKAP/RI binding, like PV38
(Burns-Hamuro et al., 2003) and RIAD (Carlson et al., 2006) were
put in use. Besides the improvements regarding binding aﬃnity
to distinguish between AKAP binding to RI or/and RII, a big
limitation is the cell permeability of the designed peptides. Several
approaches have been used to address this problem by attaching
a cell-permeable poly-basic sequence to the disruptor peptide,
like the TAT or antennapedia sequences or a poly-arginine
peptide. For example, a peptide derived from the TAT protein
of the human immunodeﬁciency virus (HIV-1) can, when linked
to the disruptor peptide, easily facilitate its transport into the
cell. TAT-AKAP-IS could at micromolar concentrations disrupt
endogenous AKAP/PKA interaction and aﬀect PKA subcellular
localization in insulin-secreting pancreatic B-cells (Faruque et al.,
2009). In perfused hearts, TAT-conjugated A-kinase-anchoring
disruptor (TAT-AKAD) aﬀected heart rate and contractility
after β-adrenergic stimulation and disrupt PKA localization
in cardiomyocytes (Patel et al., 2010). Another approach that
has been developed to improve peptide permeability is to use
all-hydrocarbon-stapled α-helical peptides, where non-natural
amino acids are incorporated into the peptide resulting in
a stapled peptide that is locked in a α-helical conformation.
Additionally, it has been shown that stapled peptides have
increased binding aﬃnity, less susceptibility to proteolytic
degradation, improved pharmacologic performance and serum
half-life (Verdine and Hilinski, 2012). Using this technique,
Wang and co-workers developed disruptor peptides that are
highly cell permeable to diﬀerent cell-lines and that could
eﬃciently prevent the interaction between AKAP and PKA,
which they called Stapled Anchoring Disruptors (STADS). They
designed STAD-2 and STAD-3 (Wang et al., 2014) and RI-
STAD-1 and RI-STAD-2 (Wang et al., 2015) that are highly
selective for disrupting the interaction between AKAPs/PKA-RII
and AKAP/PKA-RI, respectively. Interestingly, STAD-2 has been
used in a very diﬀerent cell model system as a potential strategy
to study and develop new antimalarials targets (Flaherty et al.,
2015).
Even if these are highly eﬃcient peptides, the fact that
they disrupt the AKAP/PKA interaction diminishes their
speciﬁcity since this interaction is common to all PKA-AKAP
complexes. By disrupting the AKAP/PKA interaction, these
peptides will aﬀect several AKAP/PKA complexes inside the
cell regardless of the AKAP present. A much more precise
strategy would be to disrupt individual AKAP complexes, which
would be possible by preventing the interaction between a
speciﬁc AKAP and an attached substrate protein that will be
phosphorylated by PKA. There are several examples of such
peptides, which were also designed mainly as tools to study
and conﬁrm AKAP-interactions. One example is a short peptide
derived from the phospholamban (PLB) domain that binds to
AKAP18δ and competes with and displaces the AKAP18δ/PLB
interaction (Lygren et al., 2007). This PLB peptide with a poly-
arginine attached to the C- or N-terminus for penetrance in
neonatal cardiomyocytes, blocked noradrenalin-induced increase
in Ca2+ reabsorption. Another possibility would be to disrupt
the interaction between the AKAP targeting domain and
its interaction partner providing subcellular localization. For
example Dodge-Kafka et al. (2005) designed a fragment encoding
residues 585–1286 of mAKAP that displaced mAKAP from the
perinuclear membrane.
Recently, a new approach was established that uses structure-
based phage selection to design new RII D/D domain fragments
that can selectively distinguish between diﬀerent AKAPs, which
were designated RSelect (Gold et al., 2013). Using Western
blot and ampliﬁed luminescence proximity homogenous assay
(AlphaScreen) assays RSelectAKAP2 and RSelectAKAP18 were
shown to preferably interact with AKAP2 and AKAP18 in vitro.
Additionally, in vivo experiments showed that the same mutants
have a similar subcellular distribution as their AKAP partners and
they recognize and interact with them.
Even though disruptor peptides are of great importance for
interfering with PPIs and an invaluable asset to understand
cAMP/AKAP/PKA signaling eﬀectors and eﬀects, they have
limited use as therapeutics. Peptides are designed and derived
from one of the binding proteins involved. When compared
to peptidomimetics and small molecules, low permeability and
poor per-oral bioavailability are big drawbacks in peptides.
Peptidomimetics has been used also as a possible strategy for
the modulation and regulation of AKAPs by interfering with
PPIs. For example, RIAD peptidomimetics have been developed
by adding unnatural amino acids at diﬀerent positions, leading
to increased stability in serum though still retaining speciﬁcity
to disruption of the AKAP/PKA-RI interaction (Torheim et al.,
2009). In addition, a RIAD peptidomimetic (RIAD-P3) has been
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shown to limit HIV-1 viral replication and stabilize CD4 levels by
disrupting AKAP/PKA-RI in vivo (Singh et al., 2014).
When compared to peptides, small molecules oﬀer several
advantages in drug discovery: due to their smaller size they can be
synthesized easily and at a lower price, get faster to their targets,
have potential for higher oral bioavailability, can oﬀer better
stability and can be used to allosterically target quite large protein
interaction surfaces. However, one downside to this approach
is the fact that it requires detailed and profound knowledge
about the interaction between the two proteins involved and
PPI targeting can be quite challenging and make small molecule
approaches less attractive from a drug discovery point-of-view.
Several techniques have been contributing to identifying
PPIs and increasing the information regarding their structure
such as X-ray crystallography, nuclear magnetic resonance
(NMR), thermal shift assay, surface plasmon resonance (SPR),
immunoprecipitation and other biochemical assays as well as in
silico modeling of interactions. However, there are still challenges
when screening for small molecule PPI disruptors: the PPI
interfaces may be big, discontinuous or ﬂat and hydrophobic with
an absence of pockets and typically a screen yields PPI disruptors
with micromolar aﬃnity. Peptides do not have these limitations,
but have issues with stability and permeability. In order for small
molecule targeting of PPIs to be successful, a topology of the
interacting proteins with small pockets or the identiﬁcation of
key residues that contribute to the binding energy, so called “hot
spots” are necessary requirements (reviewed in Turnbull et al.,
2014). Furthermore, increasing the size and molecular weight of
the small molecule or assembling new compounds by a fragment-
based approach may overcome some of these problems. Small
molecules can also allosterically bind to one of the two interacting
proteins outside the binding interface inducing conformational
changes aﬀecting the PPI (Arkin and Wells, 2004; Fry, 2006;
Wells and McClendon, 2007; Turnbull et al., 2014).
The ﬁrst study reporting the use of small molecules as
disruptors of PPIs in AKAP complexes was in Christian et al.
(2011), when it was reported that a group of structurally similar
small molecules could prevent the interaction between an AKAP
and PKA-RII. After screening a library of 20,000 compounds,
the authors found that FMP-API-1 and its derivatives disrupted
the interaction between AKAP18δ and both RIIα and RIIβ by
allosteric binding to RII outside its D/D domain instead of
binding to the AKAP interacting surface. Using cardiomyocytes
they showed both in vitro and in vivo evidence that these small
molecules disrupt AKAP and RII binding and at the same time
activate PKA, indicating a dual eﬀect.
Increasing interest in PPI disruptors together with
improvements in high-throughput screening (HTS) for
compounds targeting PPIs has resulted in an increasing number
of projects in this area. Combinations of primary and secondary
assays in HTS can create an attractive and very useful setting
to screen fast and easily large compounds libraries. These
are normally miniaturized assays performed in a robotics
workstation, where diﬀerent instruments and liquid handling
systems are used. There are several published assays to screen
both for peptides and small molecules that were speciﬁcally
developed to target PPIs in complexes involving AKAPs such
as AlphaScreen; SPR; enzyme-linked immunosorbent assay
(ELISA); and homogenous time-resolved ﬂuorescence (HTRF)
(Stokka et al., 2006; Jarnaess et al., 2008; Christian et al., 2011;
Gold et al., 2013; Schächterle et al., 2015).
Certainly targeting PPIs is a very appealing and promising
therapeutic strategy as it is possible to speciﬁcally target
interactions in single molecules complexes at deﬁned subcellular
places that until now has not been fully address and exploited.
Therapeutic Targets in the Heart in cAMP
Signaling Pathways
Heart pathologies are a leading cause of hospitalization and
mortality in the Western World. Moreover, population growth
and increase in life expectancy accelerates the number of
heart incidents. Currently there are several treatment choices
that interfere with cAMP signaling in the heart. Beta-blockers
block adrenergic signaling and have a negative inotropic
and chronotropic eﬀect. In contrast dopamine has a positive
inotropic eﬀect and paces the heart. Beta-blockers are, however,
accompanied by signiﬁcant side eﬀects, because they aﬀect all
downstream signaling. As an alternative to beta-blockers, the
recently described biased agonists and antagonists can provide
functional selectivity, where the biased ligand activates or
terminates a speciﬁc intracellular signaling pathway downstream
of the GPCR. In this case one can achieve a more speciﬁc
and selective eﬀect rather than the “all or nothing” eﬀect of
beta-blockers (Kenakin and Miller, 2010). Particular attention
has been given to the importance of ligand bias as a new
potential therapeutic strategy for classical GPCR in cardiology
targeting angiotensin II type 1 receptors and the β-adrenergic
receptors (DeWire and Violin, 2011). With this strategy it might
be possible to attain a more precise and speciﬁc outcome
without the unwanted side eﬀects, making these ligands very
interesting drugs for new therapeutic strategies. Additionally, a
more eﬀective strategy could be to directly alter a speciﬁc AKAP
signalosome by aﬀecting a single PPI in complexes where AKAPs
have well-established roles in the heart regarding: (i) Ca2+-
handling and excitation-contraction coupling; (ii) hypertrophic
stress responses; and (iii) controlling electrical signaling. Here we
will shortly mention a few of the most relevant AKAPs targets.
(i) Ca2+-Handling and Excitation-Contraction
Coupling
In cardiac myocytes AKAP18α (also known as AKAP15) anchors
PKA to L-type Ca2+ channels in plasma membrane. It was also
shown that in skeletal muscle cells AKAP18α directly interacts
with both PKA and the channel (Hulme et al., 2002). The authors
used a peptide to disrupt the leucine zipper motif interaction
between the AKAP and the channel, inhibiting voltage-
dependent potentiation of L-type Ca2+ channel. The disruptor
peptides abolish sympathetically induced, AKAP18α-dependent
PKA phosphorylation of L-type Ca2+ channels and consequently
channel open probability. This in turn prevents Ca2+ entry
increased in response to local cAMP that increases contractility,
resembling β-blockers eﬀect.
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More recently, has also been shown that in cardiac myocytes
AKAP5 (also known as AKAP79/150) assembles a complex
in caveolin 3-associated L-type Ca2+ channels together with
β-adrenergic receptor, PKA, AC5/6 and calcineurin (CaN), which
is important for sympathetic regulation (Nichols et al., 2010).
Also, AKAP5 was shown to directly interact with L-type Ca2+
channels in HEK293 cells via modiﬁed leucine zipper motifs,
similar to AKAP18α (Oliveria et al., 2007). Taken together
this suggests that both AKAP18α and AKAP5 supra molecular
complexes are involved in sympathetically stimulated Ca2+ entry
trough L-type Ca2+ channels, likely associated with diﬀerent
channels subpopulation and cAMPmicrodomains. Additionally,
Makarewich et al. (2012) showed that these caveolin 3-associated
L-type Ca2+ channels might be an important target for cardiac
hypertrophy.
Lygren et al. (2007) found a PKA/AKAP18δ/PLB complex
that regulates SR Ca2+-ATPase 2 (SERCA2) in the heart, which
was also later shown in human myocardium (Ahmad et al.,
2015). The PLB/SERCA2 complex plays a crucial role in calcium
homeostasis in cardiomyocytes and is major regulator of cardiac
contractility in vivo (Koss and Kranias, 1996). Under normal
conditions dephosphorylated PLB inhibits SERCA2 mediated
Ca2+-reabsorption into the SR, a process that is critical for
relaxation of the cardiomyocytes and reﬁlling of the heart
before the next contraction. However, AKAP18δ acts as a
scaﬀold protein forming a complex of AKAP18δ and PKA
together with PLB/SERCA. Upon β-adrenergic stimulation, PLB
is phosphorylated and inhibition of SERCA2 is released leading
to an increase in Ca2+-reuptake into the SR allowing for pacing
the heart by facilitating faster relaxation and ﬁlling. Inhibition
of PLB phosphorylation by targeting this complex with PPI
disruptors is thought to be cardioprotective (Lygren and Taskén,
2008). Moreover, the AKAP18δ/PLB complex should be relatively
heart speciﬁc, thus minimizing potential side eﬀects. The binding
between AKAP18δ and PKA has already been targeted, both by
peptides and small molecules. Here they used HTS to screen
libraries of small molecules which inhibit the binding between
AKAP-PKA (Christian et al., 2011). Another possibility would
be to disrupt the interaction between other proteins in the
complex (Figure 3A), Lygren et al. (2007) also showed that in
neonatal cardiac myocytes the displacement of AKAP18δ/PLB
by a short peptide (13–20 aa) aﬀects the phosphorylation of
PLB on Ser16 and consequently Ca2+- re-uptake into the SR.
Also, removal/reduction of AKAP18δ by siRNA injected in adult
cardiomyocytes had the same eﬀect.
In the two previous examples the PPI disruptor approach
has been to target the binding between AKAPs and the
phosphorylated substrate. Another possibility is to target PPIs
between AKAPs and other enzymes, such as PDEs which can
potentially be good targets for therapeutic strategies since PDEs
are involved in many physiological aspects of cardiomyocyte
function, for review see (Mongillo and Zaccolo, 2006). PDEs
contribute to the regulation of small cAMP pools by anchoring
to AKAPs (Richter et al., 2008; Scott and Santana, 2010). In
rat primary cardiomyocytes both PDE3 and PDE4 are likely the
major contributors in cAMP signaling (Mongillo et al., 2004;
Rochais et al., 2004; Fischmeister et al., 2006; Mika et al., 2012).
Additionally, PDE4D are components of the supramolecular
complex formed with AKAP18δ/SERCA2 (Lygren et al., 2007;
Ahmad et al., 2015). Also in renal principal cells PDE4D
is anchored in the AKAP18δ complex (Stefan et al., 2007).
Recently, Ahmad et al. (2015) also showed that PDE3A1
also associates with the PLB/AKAP18δ/SERCA2 supramolecular
signaling complex in human myocardium SR.
(ii) Hypertrophic Stress Responses
A-kinase anchoring proteins are also present in signalosomes that
govern the cellular response known as myocardial hypertrophy,
FIGURE 3 | Possible therapeutic strategies to target protein–protein interactions (PPIs) in specific AKAP complexes in the heart. (A) Disruption of the
AKAP18γ/δ-PLB interaction prevents PLB phosphorylation on Ser16 and dislocation from SERCA2. This inhibits SERCA2 activation and consequently Ca2+ uptake
into the sarcoplasmic reticulum (SR). (B) Disruption of the nesprin-1α/mAKAP interaction promotes AKAP/PKA complex dissociation from the perinuclear membrane
and might be a strategy to reduce hypertrophy. (C) Disruption of the connexin 43-ezrin interaction could prevent PKA-mediated phosphorylation increasing
inter-cardiomyocyte conductivity which could be cardioprotective following myocardial infarction damage.
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which occurs due to diﬀerent types of cardiac stress where
increased levels of catecholamines induce transcriptional
activation evoking heart remodeling. These “hypertrophy
signalosomes” include a multicity of proteins: protein kinases,
PDEs, PPs, calcium channels and others, that all come together
in supramolecular complexes coordinated by AKAPs (reviewed
in Negro et al., 2008; Carnegie and Burmeister, 2011; Diviani
et al., 2013; Soni et al., 2014). At least two AKAPs are involved
in cardiomyocyte hypertrophy, an alternatively spliced isoform
of muscle AKAPβ (mAKAP, previously called AKAP100;
Dodge-Kafka et al., 2005) and AKAP-Lbc (Appert-Collin et al.,
2007).
One of the signalosomes that is scaﬀolded by mAKAP
includes PKA, ryanodine receptors (RyR), CaN and transcription
factors NFAT and MEF2 (Pare et al., 2005a; Li et al., 2010,
2013). In response to a cAMP increase due to β-adrenergic
stimulation, activated PKA phosphorylates RyR channels, the
Ca2+ release activates CaN, which mediates NFAT and
MEF2 transcriptional activity. NFAT and MEF2 transcriptional
activity regulated by CaN is dependent and requires mAKAP
(Li et al., 2010, 2013). Additionally, Li et al. (2013) showed that
cardiomyocytes expressing a mCherry-CaN binding site peptide
disrupts mAKAP/CaN complex and inhibits adrenergically
induced myocyte hypertrophy, providing a possible therapeutic
strategy by targeting mAKAP/CaN. Small molecules might also
be potential candidates, since it was already shown that they
eﬃciently disrupt the PPI between CaN and NFAT in T cells
(Roehrl et al., 2004).
It has also been shown that mAKAP binds directly
to phospholipase C∈ (PLC∈; Zhang et al., 2011), which
generates diacylglycerol (DAG) at the nuclear envelope using
as substrate phosphatidylinositol 4-phosphate (PI4P) from the
Golgi apparatus, leading to activation of protein kinase D
(PKD; Zhang et al., 2013). The formation of this complex
and its involvement in myocyte hypertrophy has been shown
using siRNA based depletion of PLCε and observing that this
prevents development of cardiac hypertrophy (Zhang et al.,
2011, 2013). Recently, it was shown that histone deacetylase
(HDAC) 4 and PKD, which phosphorylates HDAC4 also
resides in this AKAP complex (Kritzer et al., 2014). In vivo
evidence showed that mAKAP knockout mice have better
chance of survival when cardiac hypertrophy is induced both
by pressure and catecholamine overload. It was also shown that
mAKAP knockout decreased apoptosis, ﬁbrosis and pathological
gene expression via decreasing activation/phosphorylation of
PLC∈/PKD1/HDAC4 complex proteins (Kritzer et al., 2014).
Taken together these data provides a novel therapeutic target
between mAKAP/PLC∈ for chronic hypertrophy.
Another potential PPI target is that of the AKAP targeting
domain and its localization partner. mAKAP is localized in the
perinuclear membrane, however, it is not a transmembrane
protein, but binds to the outer nuclear membrane protein
nesprin-1α (Pare et al., 2005b). Dodge-Kafka et al. (2005)
showed that the supramolecular mAKAP/PDE4D3/Epac/ERK5
complex modulates cardiomyocytes hypertrophy. Brieﬂy,
mAKAP anchored PKA phosphorylates PDE4D3 that hydrolyses
local cAMP forming a negative feedback loop. At the same time
PDE4D3 that binds to Epac1and ERK5 can induce cardiomyocyte
hypertrophy. Additionally, RNA interference of mAKAP or
disruptor peptides competing for the mAKAP/perinuclear
membrane binding site blocks the cytokine induced
cardiomyocyte growth (Figure 3B) (Dodge-Kafka et al., 2005).
AKAP-Lbc acts as a scaﬀold protein for several protein
kinases: PKA, protein kinase C (PKC) and PKD that
phosphorylate diﬀerent substrates leading to hypertrophy,
additionally AKAP-Lbc can also acts as a guanine nucleotide
exchange factor (GEF) for the small GTPase Rho (reviewed in
Carnegie and Burmeister, 2011; Diviani et al., 2013; Soni et al.,
2014).
Unlike the mAKAP complex, PKA binding to AKAP-Lbc leads
to myocyte cardioprotection. Recently it was demonstrated that
PDE4 directly binds to heat-shock protein of 20 kDa (Hsp20)
in the heart (Sin et al., 2011). HSPs are chaperone proteins
that are important for normal cell function; moreover, their role
in protecting against ischemia-reperfusion injury, apoptosis and
hypertrophy is well known (Fan et al., 2006; Edwards et al.,
2011; Fan and Kranias, 2011). Edwards et al. (2012) showed the
involvement of AKAP-Lbc which anchors PKA and Hsp and is
responsible for directing PKA phosphorylation of Hsp20, which
is cardioprotective (Lee et al., 2013). In contrast, in the absence of
cAMP stimulation PDE4 hydrolyses the basal levels of cAMP and
prevents activation of PKA resulting in unphosphorylated Hsp20
(Edwards et al., 2012). Furthermore, targeting the Hsp20-PDE4D
interaction with a disruptor peptide reduced the development of
pressure overload hypertrophic response in aortic-banded mice
(Martin et al., 2014). Moreover, small molecules might oﬀer a
potential therapeutic avenue since they have already been shown
to modulate Hsp20 activity in human airway smooth muscle (An
et al., 2011).
As previously mentioned AKAP-Lbc also recruits PKC and
PKD1 which enables phosphorylation and activation of PKD1 by
PKC (Carnegie et al., 2004), the activated PKD1 is then released
from the complex to phosphorylate HDAC5, which has also
been shown to be involved in hypertrophy (Zhang et al., 2002;
Vega et al., 2004). Additionally, disruption of AKAP-Lbc/PKD1
interaction by truncating AKAP-Lbc in mouse models aﬀects
hypertrophy induced by transverse aortic constriction (TAC)-
induced pressure overload (Taglieria et al., 2014).
Finally AKAP-Lbc can act as a GEF for the small GTPase
Rho and this signalosome can be a possible target for preventing
hypertrophy. It was also shown that due to α-adrenergic receptor
stimulation, AKAP-Lbc assembles RhoA eﬀectors PKNα, MLTK,
MKK3 leading to activation of p38 MAPK (Cariolato et al.,
2011) and that this complex regulates hypertrophic responses
in the stressed heart (Pérez López et al., 2013). Furthermore,
the authors showed by breeding transgenic mice overexpressing
a disruptor peptide that inhibition of AKAP-Lbc/p38 complex
reduces cardiomyocyte hypertrophy, proving for the ﬁrst time an
in vivo role of AKAP in regulating cardiac hypertrophy (Pérez
López et al., 2013).
It is also important to mention that cardiomyocyte
hypertrophy may sometimes be beneﬁcial and other times
harmful (reviewed in Crozatier and Ventura-Clapier, 2015).
In some of the studies mentioned targeting AKAPs decreases
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compensatory hypertrophy, which can lead to apoptosis and
heart failure. Nevertheless, targeting such AKAP complexes
may prove useful in combination with other pharmacological
approaches.
(iii) Controlling Electrical Signaling
A-kinase anchoring proteins also play a role in promoting
electrical cell-to-cell coupling. Gap junctions play a crucial role
in cell-to-cell conductance in cardiomyocytes. These channels
are composed of connexin 43 (Cx43) hexamers creating pores
throught the cell membrane of two adjacent cells allowing passage
of the signal. It has recently been shown that an AKAP, ezrin,
is involved in the expression and regulation of gap junction
conductivity by organizing a PKA/Cx43/ezrin supramolecular
complex in other cell types (Pidoux et al., 2014). Moreover, it is
known that Cx43 is involved in several pathological conditions
in the heart (reviewed in Severs et al., 2008). For example
during ischemia, gap junctions are aﬀected mainly by changes in
phosphorylation of Cx43 (Beardslee et al., 2000; Axelsen et al.,
2006). Targeting the PPIs between the AKAP and Cx43 in the
heart may create a possible therapeutic strategy since Cx43 gap
junction communication is damaging in the post-infarction heart
(Figure 3C).
Conclusion
Evidence that cAMP compartmentation is particularly important
for transmission of accurate and speciﬁc biological information
is increasing. In order to respond to local cAMP gradients
AKAPs contribute to correct and speciﬁc propagation of
the cAMP signal by organizing supramolecular complexes
where PKA, its substrates and other signaling proteins
are assembled. These complexes come together through
PPIs, which are fundamental for correct propagation of
the response. Until recently targeting AKAP interactions
by designing peptides to disrupt such binding interfaces
was predominantly used as a tool to study function of
components of these signalosomes. Currently, there is growing
interest in the possibility to develop small molecule PPI
disruptors which creates new opportunities for developing
therapeutic strategies by preventing interactions in AKAP-
complexes. Here we suggest some possible target complexes
in the heart, however, other potential targets were not
mentioned and more may still be discovered. Finally, we expect
that targeting PPIs in complexes organized by AKAPs will
receive increased attention as knowledge in development of
small molecule PPI disruptors increases and the beneﬁts of
speciﬁcally perturbing individual signaling complexes come
out.
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